News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,100 Results
Type
Article (39745)
Company Profile (248)
Press Release (660107)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204188)
Career Advice (2008)
Deals (35421)
Drug Delivery (95)
Drug Development (81055)
Employer Resources (172)
FDA (16192)
Job Trends (14865)
News (345235)
Policy (32548)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (86)
Alliances (49444)
ALS (95)
Alzheimer's disease (1385)
Antibody-drug conjugate (ADC) (132)
Approvals (16190)
Artificial intelligence (265)
Autoimmune disease (22)
Automation (17)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (106)
Biotechnology (176)
Bladder cancer (79)
Brain cancer (27)
Breast cancer (292)
Cancer (2323)
Cardiovascular disease (179)
Career advice (1677)
Career pathing (30)
CAR-T (156)
Cell therapy (439)
Cervical cancer (20)
Clinical research (66097)
Collaboration (857)
Company closure (2)
Compensation (570)
Complete response letters (19)
COVID-19 (2590)
CRISPR (41)
C-suite (251)
Cystic fibrosis (102)
Data (2338)
Decentralized trials (2)
Denatured (19)
Depression (44)
Diabetes (275)
Diagnostics (6382)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (121)
Drug pricing (105)
Drug shortages (25)
Duchenne muscular dystrophy (97)
Earnings (87085)
Editorial (39)
Employer branding (21)
Employer resources (146)
Events (112674)
Executive appointments (746)
FDA (17575)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (775)
Gene editing (109)
Generative AI (20)
Gene therapy (315)
GLP-1 (719)
Government (4432)
Grass and pollen (4)
Guidances (163)
Healthcare (18821)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (125)
Indications (29)
Infectious disease (2735)
Inflammatory bowel disease (143)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (98)
Interviews (312)
IPO (16530)
IRA (40)
Job creations (3634)
Job search strategy (1422)
Kidney cancer (10)
Labor market (43)
Layoffs (475)
Leadership (17)
Legal (7910)
Liver cancer (76)
Lung cancer (325)
Lymphoma (157)
Machine learning (9)
Management (58)
Manufacturing (329)
MASH (77)
Medical device (13385)
Medtech (13390)
Mergers & acquisitions (19468)
Metabolic disorders (708)
Multiple sclerosis (83)
NASH (16)
Neurodegenerative disease (94)
Neuropsychiatric disorders (27)
Neuroscience (1945)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (40)
Obesity (371)
Opinion (205)
Ovarian cancer (81)
Pain (91)
Pancreatic cancer (88)
Parkinson's disease (154)
Partnered (22)
Patents (245)
Patient recruitment (116)
Peanut (46)
People (57353)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20595)
Phase II (29114)
Phase III (21677)
Pipeline (1387)
Policy (147)
Postmarket research (2563)
Preclinical (8763)
Press Release (64)
Prostate cancer (108)
Psychedelics (30)
Radiopharmaceuticals (247)
Rare diseases (385)
Real estate (5907)
Recruiting (65)
Regulatory (22329)
Reports (48)
Research institute (2321)
Resumes & cover letters (349)
Rett syndrome (6)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (132)
Series B (91)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3580)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (51)
The Weekly (30)
Vaccines (699)
Venture capitalists (42)
Weight loss (237)
Women's health (36)
Worklife (16)
Date
Today (128)
Last 7 days (952)
Last 30 days (3237)
Last 365 days (32438)
2025 (11991)
2024 (35219)
2023 (40076)
2022 (51174)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35020)
2017 (32111)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (54)
Alaska (7)
Arizona (233)
Arkansas (13)
Asia (37884)
Australia (6194)
California (6438)
Canada (2073)
China (539)
Colorado (274)
Connecticut (282)
Delaware (159)
Europe (81417)
Florida (959)
Georgia (216)
Idaho (57)
Illinois (547)
India (25)
Indiana (323)
Iowa (11)
Japan (173)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (923)
Massachusetts (4785)
Michigan (226)
Minnesota (406)
Mississippi (2)
Missouri (82)
Montana (27)
Nebraska (25)
Nevada (68)
New Hampshire (63)
New Jersey (1798)
New Mexico (28)
New York (1813)
North Carolina (992)
North Dakota (8)
Northern California (2843)
Ohio (210)
Oklahoma (14)
Oregon (34)
Pennsylvania (1432)
Puerto Rico (13)
Rhode Island (33)
South America (1097)
South Carolina (26)
South Dakota (1)
Southern California (2417)
Tennessee (106)
Texas (957)
United States (24108)
Utah (188)
Virginia (152)
Washington D.C. (64)
Washington State (566)
West Virginia (3)
Wisconsin (58)
700,100 Results for "therapeuticsmd inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
TherapeuticsMD Announces First Quarter 2025 Financial Results
May 14, 2025
·
4 min read
Press Releases
TherapeuticsMD Announces Full Year 2024 Financial Results
March 28, 2025
·
4 min read
Business
TherapeuticsMD Announces First Quarter 2024 Financial Results
TherapeuticsMD, Inc., a company that owns rights to pharmaceutical royalties, reported financial results for the first quarter ended March 31, 2024.
May 10, 2024
·
5 min read
Business
TherapeuticsMD Announces Full Year 2023 Financial Results
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023.
March 29, 2024
·
5 min read
Press Releases
TherapeuticsMD Announces Third Quarter 2024 Financial Results
November 12, 2024
·
4 min read
Business
TherapeuticsMD Announces Third Quarter 2023 Financial Results
TherapeuticsMD, Inc., a company that owns rights to pharmaceutical royalties, reported financial results for the third quarter ended September 30, 2023.
November 14, 2023
·
6 min read
Business
TherapeuticsMD Announces Second Quarter 2023 Financial Results
TherapeuticsMD, Inc., a company that owns rights to pharmaceutical royalties, reported financial results for the second quarter ended June 30, 2023.
August 14, 2023
·
4 min read
Business
TherapeuticsMD Announces First Quarter 2023 Financial Results
TherapeuticsMD, Inc., a company that owns rights to pharmaceutical royalties, reported financial results for the first quarter ended March 31, 2023.
May 15, 2023
·
4 min read
Business
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
TherapeuticsMD, Inc. today reported financial results for the full year ended December 31, 2022.
April 7, 2023
·
6 min read
Business
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TherapeuticsMD,” “TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited.
January 3, 2023
·
5 min read
1 of 70,010
Next
